Price
chg
chg neg
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
low api
52 wk hi
high api
Cash
$42.2M
Burn Rate (Qtr)
$4.5M
Mkt Cap
mkt cap api
Avg Volume
volume api
*cash/burn updated:
Q4 '21
Drug Pipeline
Click the button to see the updated pipeline
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
TLSA
Company Profile
Tiziana Life Sciences is a dual-listed* (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.
*Note: Our market cap for TLSA is likely not accurate because its shares are listed on both the London Stock Exchange and the NASDAQ.
Recent Posts
See what the community is saying - click to see full post.